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Abstract
Influenza is an infectious disease causing huge medical and economic losses. Influenza 
pathogenesis is associated with two processes in the human body: (i) lung damage due 
to viral replication in the columnar ciliary epithelium of bronchi and bronchioles and (ii) 
inflammatory burst inducing an increase in reactive oxygen species generation that causes 
extensive damage in cellular membranes of the small vessels. The oxidative stress in influ-
enza virus-infected organism provokes free-radical oxidation of unsaturated lipid chains in 
the cell membranes. As vitamin E is a lipid-soluble substance and possesses a hydrophobic 
tail, it tends to accumulate within lipid membranes. There, it acts as the most important 
chain breaker, reacting with lipid peroxyl radicals much faster than they can react with adja-
cent fatty acid side chains. Among the antioxidants tested in influenza virus infections in 
mice, vitamin E occupies the leading position because of its efficacy in preventing oxidative 
damage through its free-radical scavenging activity. Although vitamin E is not possessing 
specific antiviral action, its antioxidant effect probably plays important role in lung and liver 
protection. Attention should be paid to the synergistic character of antiviral effect of the 
combination vitamin E and oseltamivir. Vitamin E could be recommended as a component 
in multitarget influenza therapy.
Keywords: flu pathogenesis, oxidative stress, vitamin E, combination with antivirals, 
influenza therapy
1. Influenza
Influenza is an acute infectious disease that exerts a very great effect on human society, caus-
ing huge medical and economic losses. Influenza usually occurs in annual seasonal (winter) 
outbreaks or epidemics (in moderate temperature climates). Moreover, influenza pandemics 
periodically attack the populations of all continents. People of all ages are affected, but the 
prevalence is greatest in school-age children. The disease’s severe course, complications, and 
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mortality are greatest in infants, the elderly, and those with underlying illnesses—chronic 
pulmonary or cardiovascular diseases, and diabetes mellitus. The severe complications 
include hemorrhagic bronchitis or pneumonia (primary viral or secondary bacterial). In addi-
tion, fulminant fatal influenza viral pneumonia can occur, with death proceeding in as little 
as 48 hours after the initial flu symptoms [1]. The World Health Organization recommends 
influenza vaccines as a main tool for preventing infection and anti-influenza chemothera-
peutics with antiviral drugs for treatment and/or prophylactically [1]. The antivirals effective 
against influenza are divided into two types based on their modes of action: (i) inhibitors of 
the neuraminidase—oseltamivir, zanamivir, peramivir, and related compounds, efficacious 
against influenza A and B virus infections, and (ii) blockers of the protein M2—rimantadine-
HCl and amantadine-HCl, active against influenza virus A infections. Although both types of 
agents have proven antiviral effectivity, the rate of drug resistance is constantly increasing, 
especially for M2 blockers [2].
Two principal problems are related with vaccine prevention: (i) anti-influenza vaccines com-
monly demonstrate 70–90% effectivity in young persons, with rates markedly decreasing in 
the elderly; (ii) the protection length is limited to a few months or a season because of the 
continuous viral antigenic drift based on gradually accumulated mutations, requiring annual 
revaccination [3].
2. Influenza pathogenesis
The pathogenesis of influenza virus infection is associated with two general processes in the 
human body: (i) local lung damage due to viral replication in the columnar ciliary epithelium 
of bronchi and bronchioles, which leads to progressive damage of the alveolar cells, broncho-
pneumonia (viral or combined viral-bacterial), massive bronchitis (including bronchiolitis), 
and the like, as the major causes of death [4]; (ii) a dramatic inflammatory burst that induces 
among other processes an increase in reactive oxygen species generation, causing extensive 
damage in cellular membranes, predominantly in the small vessels, arterioles, and capillar-
ies [5–8]. In addition, extrapulmonary complications affect many organs and tissues, such as 
heart, brain, middle ear, liver, and endocrines, and even stomach and kidneys, though that is 
rare [9–14].
2.1. Respiratory tract damages
Influenza virus replicates in the respiratory tracts of humans, mainly in the lungs. 
Extrapulmonary multiplication of this virus has not been proven in people with influenza, 
nor in experimental conditions in influenza virus-infected laboratory animals. Influenza virus 
replicates throughout the whole respiratory tree. Tracheobronchitis is the common clinical 
picture of influenza. In the acute stage, multifocal destruction and desquamation of the 
columnar epithelium of the trachea and bronchi accompanied with edema and congestion of 
the submucosa are characteristic. In about 50% of cases, tracheitis and bronchitis have a hem-
orrhagic character. Cell necrosis is the final stage of desquamation of the affected epithelium 
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with concomitant attainment of the mucus glands. Small- and medium-sized bronchioles are 
strongly affected by the processes seen in the larger airways, with an entirely necrotic bron-
chiolar wall associated with polymorphonuclear cell infiltrate. Influenza virus pneumonia 
very often proceeds to secondary bacterial pneumonias. Destruction of alveolar epithelium 
and endothelium can worsen the severity of lung injury [4, 15].
Lung disorders in influenza virus infection may be triggered by: (i) a massive infiltration of 
leukocytes, mainly polymorphonuclear leukocytes, into the alveolar space; (ii) a decrease in 
the partial pressure of oxygen, causing the development of hypoxia; (iii) an increase in the 
partial pressure of CO2 and development of metabolic acidosis; (iv) a “cytokine storm”—a release of cytokines, eicosanoids and prostaglandin E2 and an enhanced immune response; 
and (v) the development of oxidative stress [5, 7, 16, 17].
Our previous data and that of most of the literature showed that experimental influenza virus 
infection in susceptible laboratory animals (mice and ferrets) imitates the above influenza 
clinical picture: progressive damage of the alveolar cells, acute inflammatory reaction, and 
development of massive bronchitis and probably pneumonia, in parallel with a decrease in 
endogenous lipid- and water-soluble antioxidants levels, as well as the compensatory changes 
of antioxidant enzyme activities [18–21].
2.2. Oxidative stress in influenza virus infection
Lungs are the target organs of the influenza virus. However, in the course of influenza virus 
infection, dynamic changes in oxidative metabolism, provoked by the overgeneration of ROS 
(reactive oxygen species) and the activation of neutrophils, can reach the development of 
oxidative stress [5, 18, 19, 22–24]. Oxidative stress is defined as a disturbance of the proox-
idant-antioxidant balance in favor of prooxidants. Influenza viruses are known to induce 
ROS-generating enzymes and to disturb antioxidant defenses [5, 18, 19, 25], causing changes 
in antioxidant enzyme activity [5] and decreases in endogenous low-molecular-weight anti-
oxidants. Overgeneration of ROS may influence signaling pathways by activating “redox 
switches” [26]. In lungs, redox homeostasis is crucial in the pathology of influenza because 
it is associated with cytokine production, inflammation, cell death, and other pathological 
processes that could be triggered by enhanced ROS generation (Figure 1).
Since the products of oxidative stress possess high cytotoxic activity, it is very important to 
study mechanisms of detoxification in the infected body. After the epithelial cells are infected, 
tissue-resident alveolar macrophages are the first responders to viral infection in the lungs 
(Figure 1). They can promote viral clearance through the phagocytosis of viral particles or 
infected apoptotic cells (efferocytosis) and the release of a plethora of inflammatory cytokines 
and chemokines to initiate and drive the immune response [27–30] . Due to the ability of ROS to 
react with almost any kind of biological molecule, including proteins, lipids, and nucleic acids, 
their elevation is generally associated with genome instability, dysfunction of organelles, and 
apoptosis [31].
Antioxidant defense mechanisms, including enzymes like superoxide dismutase, catalase, and 
small molecules such as vitamins C and E and glutathione, protect tissues against oxidants [32].
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Vitamin E is the most active natural fat-soluble antioxidant capable of protecting unsaturated 
fatty acids in cellular membranes from peroxidation, thereby contributing to membrane sta-
bility [33]. Both human clinical trials and animal studies have shown a beneficial effect of 
supplemental vitamin E on the immune system [34].
Studies in the last decade established that the nuclear factor (erythroid-derived 2)-like 2 (NRF2) 
encoded in humans by the NSF2 gene, is a protein regulating the expression of antioxidant 
proteins that protect against oxidative damage triggered by injury and inflammation. NRF2 
controls the basal and induced expression of antioxidant response element-dependent genes 
to regulate the physiological and pathophysiological outcomes of oxidant exposure. NRF2 has 
a substantial impact on oxidative stress and toxicity, regulating the antioxidant defense [35].
At this point of view, the oxidative stress is caused by the imbalance between production of 
reactive oxygen species (ROS) and the body’s ability to detoxify the reactive intermediates.
Recent studies described the role of NRF2 gene coded protein in the development of oxidative 
stress. The antioxidant pathway controlled by NRF2 is pivotal for protection of lungs against 
the development of influenza virus infection-induced pulmonary inflammation and injury 
under oxidative conditions. The NRF2-mediated antioxidant system is essential to protect the 
lungs from oxidative injury and inflammation induced by influenza virus infection [36, 37].
Figure 1. Respiratory tract damages, causes by influenza virus infection.
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3. Vitamin E and influenza virus infection
It has been proven that oxidative stress in the influenza virus-infected organism provokes 
free-radical oxidation of unsaturated lipid chains in the cell membranes (lipid peroxidation), 
which reduces their permeability as a whole. In the presence of antioxidant deficiency, as 
described below, when all cell membranes are exposed and/or damaged, influenza infection 
proceeds with severe pathology and results in serious damage at all levels in the body [38].
It was established that, during influenza infection in mice, the activity of antioxidant enzymes 
SOD and catalase were changed, along with a decrease of the amounts of endogenous low-
molecular-weight antioxidants such as α-tocopherol (Table 1), glutathione, and ascorbate 
[19, 24, 39–41],). Endogenic levels of vitamin E were significantly decreased in lung, liver, 
and blood plasma [19, 23, 42]. In addition, changes in cytochromes were recorded as well 
as decreases in the activities of liver cytochrome P-450-dependent monooxygenases [18, 43]. 
Together, these facts indicate that, in the course of the disease, the buffering capacity of the 
organism’s antioxidant protection diminished [18, 19, 22, 23, 25].
These data demonstrate that, during influenza virus infection, a decrease in natural antioxi-
dant vitamin E was established, accompanied by a significant increase in endogenous lipid 
peroxidation products.
Oxidative damage in the course of influenza virus infection is quite large, even when regis-
tered in experimental animals (mice) at low virus-inoculation doses. In conditions involving 
non-infected animals with suppressed antioxidant defense systems, the consequent inocula-
tion of influenza virus resulted in an acceleration of oxidative stress and graduated tissue 
damage.
Different conditions can favor the host’s susceptibility to influenza virus infection; among 
them are cold exposure and stressors of physical, chemical, and psychological origin. For 
example, immobilization and cold-restraint stress are widely used experimental models that 
are accompanied by a considerable decrease in the antioxidative capacity of the animal organ-
ism; they are also used for the indirect modulation of antioxidant deficiency in experimental 
animals [19, 44–47].
Because of the significant role of oxidative stress in the pathogenesis of influenza virus infec-
tion, a lot of work has been done to test the influence of antioxidants on the course of influ-
enza. Drugs stimulating NRF2 pathway are tested for treatment of diseases causing oxidative 
Group Lung Liver Blood plasma
5th day 7th day 5th day 7th day 5th day 7th day
I Control 2.2 ± 0.31 2.14 ± 0.26 4.94 ± 0.51 5.4 ± 0.42 1.8 ± 0.065 1.72 ± 0.07
II Flu 1.47 ± 0.14 1.7 ± 0.17 3.35 ± 0.42 3.12 ± 0.37 1.46 ± 0.035 1.2 ± 0.37
Values are expressed as means ± SEM [41].
Table 1. Endogenous content of vitamin E [nmol/mg protein] in lung, liver, and blood plasma of mice experimentally 
infected with influenza virus A/Aichi/2/68 H3N2 (1.5 MLD50).
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stress, influenza virus infection included [48]. Experiments on in vivo models, predominantly 
in mice, hold a significant place in such investigations.
Among the antioxidants tested against influenza virus infections in mice [17, 49–52] 
α-tocopherol (vitamin E) occupies the leading position. This is because of its efficacy in pre-
venting oxidative damage through its free-radical scavenging activity [16, 18, 24, 42, 53–55].
Protein expression of NRF2 is found to be increased in both the cholesterol-fed and the vita-
min E-supplemented rabbits via activation of NRF2 pathway, resulting in induction of sev-
eral antioxidant genes. Vitamin E appeared to afford the protection effect of NRF2 [48, 55]. 
Besides, it was found that vitamin E prevents the NRF2 suppression by allergens in alveolar 
macrophages, proved for asthmatic model in vivo [56, 57].
These data clearly show the role of antioxidants, such as vitamin E, which can be manifested 
in several ways: (i) to capture free radicals in enzymatic or non-enzymatic mechanism(s), (ii) 
to suppress their generation, and (iii) to affect these processes in an indirect way, for example, 
by inhibiting viral replication.
As vitamin E is a lipid-soluble substance and possesses a hydrophobic tail, it tends to accumu-
late within the interior of lipid membranes. There, it acts as the most important chain-breaker, 
as it reacts with lipid peroxyl radicals about four times faster than they can react with adjacent 
fatty acid side chains. It is well known that vitamin E is able to prevent oxidative damage 
[58–61], because its lipophilic structure contributes to easy and passive diffusion through the 
cell membranes, allowing it to reach the mitochondria and the single-plated reticulum. In this 
way, vitamin E protects them against lipid peroxidation and damage (Figure 2). Especially 
important is its termination of free-radical chain reaction, which protects membrane polyun-
saturated fatty acids from oxidation involving reactive oxygen species [61].
Vitamin E is known to affect inflammatory responses in different tissues, including the lung, 
not only via direct quenching of oxidative stress [42, 62], but also through modulation of oxida-
tive eicosanoid pathways and prostaglandin synthesis [58, 63, 64], inhibition of inflammatory 
mediators [59], and control of apoptotic lipid signaling [60]. A stabilizing role of Vitamin E 
has a stabilizing role for membrane phospholipids [61] (Figure 2).
Figure 2. “Bermuda triangle” composed by the pathogenesis of influenza virus infection in the infected body. Vitamin 
E action is directed to the storm center.
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Several different non-antioxidant functions of vitamin E may be essential for the maintenance 
of cell integrity and functions, such as its role as an anti-phospholipase A2 agent, that is, as a 
stabilizer of the lipid bilayer of membranes against hydrolyzed and oxidized lipids [65].
The in vivo investigations on influenza virus-infected laboratory animals and the clinical data 
on influenza patients revealed a negative correlation between pulmonary inflammations and 
endogenous levels of vitamin E in the body. Exogenous vitamin E supplementation has been 
tied to reducing severe symptoms of lung disease [16, 18, 24, 66].
It is clear that influenza virus infection is a powerful prooxidant that causes a significant 
increase in lipid peroxidation products in lung, liver, and blood plasma as well as a decrease 
in natural antioxidants (vitamin E, glutathione) and cytochrome P-450 (CYP). Moreover, in the 
liver, cytochrome c reductase and liver monooxygenases (aniline hydroxylase, ethylmorphin-
N-demethylase, analgin-N-demethylase, and amidopyrine-N-demethylase) are inhibited as 
compared to their activity in control (non-infected) animals.
4. Effects of vitamin E supplementation
As mentioned above, investigations on mice experimentally infected with influenza virus 
found that endogenous vitamin E content was significantly decreased after influenza virus 
inoculation. In addition, the amount of cytochrome P-450 in the liver and the activity of cyto-
chrome c reductase decreased by about two times on the 5th–7th days post virus inoculation. 
The decrease in cytochrome P-450 was found to correlate with increases in the concentration 
of lipid peroxidation products in liver, lung, and blood [18]. Influenza virus infection signifi-
cantly inhibits liver monooxygenase activity. As a consequence, products from the decreased 
enzymatic function accumulate in the liver, resulting in the destruction of cytochrome P-450 
and its transformation to the catalytically inactive P-420 form.
The effects of influenza virus infection on liver monooxygenases and lipid peroxida-
tion are different from the effects of the hydrophobic xenobiotic substrates of cytochrome 
P-450. Evidently, the oxidative stress induced in the liver by hydrophobic xenobiotics is a 
consequence of enhanced oxidation by cytochrome P-450-dependent monooxygenases. The 
decrease in liver monooxygenase activity resulting from influenza virus infection is accompa-
nied by increases in lipid peroxidation products in the liver, which is not a result of activation 
of cytochrome P-450-dependent monooxygenases. It may be presumed that influenza virus 
induces free-radical processes outside the liver, thus producing free radicals and/or activated 
oxygen species. These reactive compounds must diffuse or be transported over the hepato-
cyte barrier to initiate lipid peroxidation in the liver.
The protective effect of vitamin E against lipid peroxidation was dose-dependent and was 
more pronounced on the 5th day as compared to the 7th day after virus inoculation [18, 22]. 
This agrees with data from Peterhans [5] and Jacoby and Choi [38]. Vitamin E supplemen-
tation led to stabilization of cytochrome P-450. Concentrations of the hepatic cytochrome 
P-450 in infected mice reached the values found in control (non-infected animals) after 
vitamin E supplementation (120 or 240 mg/kg b.w.), because the monooxygenase activities 
were restored.
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However, researchers have shown that endogenic levels of vitamin E are significantly 
decreased in lung, liver, and blood plasma (Table 1) during the course of flu infection [21, 23, 
24, 42]. Animal and human studies have demonstrated a negative correlation between endog-
enous levels of vitamin E in the body and pulmonary inflammations, and exogenous vitamin 
E supplementation has been tied to reducing severe symptoms of lung disease [16, 18, 64].
It is well known that vitamin E is able to prevent oxidative damages [58–60].
5. Vitamin E in the influenza therapy
Currently, treatment of influenza is directed mainly at targeting the first pathogenetic com-
ponent through administration of specific antivirals. Application of correctors of influenza 
pathogenesis that are associated with controlling inflammation and oxidative stress remains 
in the background.
Among the antioxidants tested in influenza virus infections in mice [17, 49–51, 65], α-tocopherol 
(vitamin E) occupies the leading position because of its efficacy in preventing oxidative dam-
age through its free-radical scavenging activity [16, 18, 24, 42, 53–55, 66, 67].
Although vitamin E is not an agent with specific antiviral action, its antioxidant effect prob-
ably plays an important role in liver protection.
The most important question is whether vitamin E, as a natural antioxidant, could be used as 
anti-influenza agent.
In fact, the ideal protective agent against flu should fulfill several criteria: (a) it must not 
allow the formation of resistant viral strains; (b) it must have a general protective effect on the 
majority of organs; (c) it must have an acceptable toxicity profile and protective time-window 
effect; and especially importantly, (d) it must provide strong protection against the symptoms 
of emerging influenza, such as the oxidative state of the infected body.
Evidently, a more effective treatment strategy is needed. Immunomodulators have been 
proven to be highly successful in treating the flu, at least in mouse infection models [68–71]. 
Using antioxidative agents to act directly on downstream deleterious inflammation events is 
also of significant importance in flu therapy.
The preventive effects of vitamin E and vitamin C, alone and in combination, was tested 
on the damage caused by influenza virus infection [72]. Mice, infected with influenza virus 
A/2/68/(H3N2) (1.5 LD50), were administered once-daily doses of vitamin E (60 mg/kg b.w.) and vitamin C (80 mg/kg b.w.) intraperitoneally (for 3 days before virus inoculation). Vitamin 
E effectively restored lipid peroxidation levels increased by influenza virus infection. The 
effect of vitamin C was similar, but slighter. The combination (vitamin E + C) had a greater 
effect on lipid peroxidation levels than did their separate administration. P-450-dependent 
monooxygenase activity was significantly restored, and more pronounced cytochrome P-450 
content and NADPH-dependent cytochrome c reductase activity was noted. The preventive 
effect of vitamin E was stronger than that of vitamin C, but the combination (vitamin E + C) 
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had the strongest effect. The superior protective effect of the combination is probably due 
to the better interaction between hydrophobic and hydrophilic low-molecular-weight anti-
oxidants against a free-radical disease like influenza. The mechanism of this interaction is 
related to vitamin C’s ability (when situated in aqueous phase) to recycle vitamin E (located 
in membranes), repairing vitamin E’s tocopheroxyl radical. Thus, vitamin C promotes the 
function of vitamin E as a free-radical scavenger [73, 74].
An underappreciated approach in flu therapy continues to be combination administration 
regimens of specific viral replication inhibitors together with antioxidants. Therefore, inves-
tigations on the combination effects of specific anti-influenza chemotherapeutic agents and 
antioxidants are of special interest. Previously, we established a favorable combination effect 
of the antioxidant 4-methyl-2,6-ditretbutylphenol (ionol) with M2-blocker rimantadine in 
mice infected with influenza virus A(H3N2). Ionol was administered intraperitoneally in a 
3-day course (45 or 75 mg/kg daily) before virus inoculation, and rimantadine (oral applica-
tion of 15 mg/kg) was administered for 5 days following the day of infection [75].
Recently, a strong beneficial effect of the combination of α-tocopherol (a component of vita-
min E) and oseltamivir was demonstrated in the treatment of experimental infection with 
influenza virus A/H3N2 in mice [76]. The results showed that this combination of agents 
simultaneously suppressed the two main processes in the pathogenesis of influenza—the 
development of pulmonary lesions in the respiratory tract as a result of virus replication and 
the oxidative stress damage to membranes of small vessels and other tissues in the body—
thus characterizing it as a very good prospect for flu therapy.
However, a question arose: Is oseltamivir an antioxidant? We used some model systems to 
test oseltamivir’s ability to scavenge superoxide radicals, to inhibit their generation, and to 
influence Fe2+ or (Fe2+-EDTA)-induced lipid peroxidation in liposomal egg suspension and in 
lung and liver microsomes [77]. We concluded that the reduction of oxidative stress in vivo 
is not connected with oseltamivir’s effect on the development of free-radical processes in the 
organism. Oseltamivir’s effect on oxidative stress in the course of viral infection could be 
explained by its specific therapeutic effect, which is connected with suppression of viral rep-
lication in the target organ.
The in vivo antiviral activity of the combination vitamin E + oseltamivir, expressed by a 
marked protective effect on the survival of influenza A virus-infected animals, was recorded 
when vitamin E was administered simultaneously with oseltamivir phosphate via a 5-day 
course post virus inoculation [76]. This effect was not observed when the vitamin E course 
started 120 or 48 hours before viral inoculation. According to this study, vitamin E applied 
individually had no effect on the course of influenza A virus infection caused by 10 MLD50. Only a lower value of the lung index was registered. In our previous study, we established a 
protective effect of vitamin E at virus infection with 2 MLD50 [18, 24].
Special attention should be paid to the sharp synergistic character of the antiviral effect of 
the combination vitamin E and oseltamivir at a dose of 0.625 mg/kg administered simultane-
ously, which resulted in the following: (i) a pronounced increase in the protection index, 
attaining 76%, and a lengthening of the MSD by 3.2 and 4 days; (ii) a pronounced decrease in 
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lung infectious virus titer; and (iii) a strong reduction in lung lesions. Oseltamivir at the same 
dose applied separately did not manifest antiviral activity.
The observed phenomenon of a strong oseltamivir dose-dependence of the combined anti-flu 
effect attaining a pronounced synergism at the lowest tested dose of 0.625 mg/kg merits a 
special attention. One explanation for this phenomenon could be the interaction of these two 
agents related to their specific mechanisms of action on the viral target structures in the lung. 
It is well known that vitamin E is included in the cellular lipid bilayer, thus decreasing cel-
lular membrane permeability [60, 62, 64]. Oseltamivir, for its part, mimics cellular neuraminic 
acid, thus interfering with the exit process of the new progeny virions [78, 79]. These two 
processes run in parallel, thus opposing the virus infection course on the cellular level. The 
two substances most likely compete in the modification of cellular membranes through their 
specific mechanisms of action. Therefore, the place of emerging synergism for oseltamivir and 
vitamin E is most likely the cell membrane in the viral target area in the lung.
Тhe favorable (even synergistic) type оf interaction between vitamin E and oseltamivir was 
absent when vitamin E was administered for 5 days before virus inoculation—that is, before 
the onset of the oseltamivir course.
The described results suggest that vitamin E has an important place as a component of the 
complex therapy of epidemic flu when administered simultaneously with chemotherapeutic 
agents, such as neuraminidase inhibitors. Moreover, in addition to its membrane protective 
effect in the influenza virus target area, vitamin E manifests pronounced activities as an anti-
oxidant agent and as a protein kinase C inhibitor and a protector of lung tissue during inflam-
matory lung illnesses [59, 80]. The study discussed above [76] convincingly demonstrates a 
strong beneficial effect of the combination of vitamin E and oseltamivir in the treatment of 
experimental infection with influenza virus A/H3N2 in mice.
The results show that this combination of agents simultaneously suppresses the two main 
processes in the pathogenesis of influenza, the development of pulmonary lesions in the 
respiratory tract resulting from virus replication and the oxidative stress damage to the mem-
branes of small vessels and other tissues in the body, thus characterizing it as a very likely 
prospect in the therapy of flu.
In summary, vitamin E could be recommended as a reliable agent, a component in multitarget 
influenza therapy.
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